Skip to main content

Advertisement

SpringerLink
Log in

Role of Inflammation in Heart Failure

  • Evidence Based Medicine (L. Roever, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This paper aims to discuss the interactions between inflammatory cytokines, immune cells, and heart failure (HF). The association of heart failure with inflammation has led to multiple studies on anti-inflammatory agents in acute and chronic heart failure.

Recent Findings

Recent findings have implicated leukocytes subclasses and multiple inflammatory mediators in the progression of heart failure and cardiovascular disease. Studies have discovered further details on the interaction between immune cells—particularly macrophages and lymphocytes—and inflammation. There are both cell-mediated and cytokine-mediated pathways of inflammation, which are interconnected. Additionally, a number of markers have been used and studied in heart failure disease progression.

Summary

In this review, we discuss inflammatory biomarkers and immune cell mediators involved in HF. We will focus on the correlations and role of these inflammatory mediators in the genesis of HF. We will also discuss the evidence on beneficial effects of anti-inflammatory agents in the setting of chronic HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century. Heart. 2003;89(1):49–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–9.

    Article  CAS  PubMed  Google Scholar 

  3. • Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–68. This review discusses the role of inflammation and heart failure, in light of new understanding of innate immunity.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–41.

    Article  CAS  PubMed  Google Scholar 

  5. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19(9):819–24.

    Article  CAS  PubMed  Google Scholar 

  6. Awad AE, Kandalam V, Chakrabarti S, et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010;298(3):C679–92.

    Article  CAS  PubMed  Google Scholar 

  7. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–6.

    Article  CAS  PubMed  Google Scholar 

  8. Van Tassell BW, Seropian IM, Toldo S, Mezzaroma E, Abbate A. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013;62(7):637–40.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949–58.

    Article  CAS  PubMed  Google Scholar 

  10. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008;153(Suppl 1):S414–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol. 2007;102(5):393–411.

    Article  CAS  PubMed  Google Scholar 

  13. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122(2):145–55.

    Article  CAS  PubMed  Google Scholar 

  14. Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69(1):164–77.

    Article  CAS  PubMed  Google Scholar 

  16. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, et al. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.

    Article  PubMed  Google Scholar 

  17. Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2001;16(1):68–75.

    Article  Google Scholar 

  18. Trofimov ES, Poskrebysheva AS. Study on activity of inflammatory factors in patients with chronic heart failure depending on the stage of the disease and NYHA class. Bull Exp Biol Med. 2015;158(5):614–6.

    Article  CAS  PubMed  Google Scholar 

  19. Li XF, Pan D, Zhang WL, Zhou J, Liang JJ. Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients. Genet Mol Res. 2016;15(2).

  20. Zhou SF, Yuan J, Liao MY, Xia N, Tang TT, Li JJ, Jiao J, Dong WY, Nie SF, Zhu ZF, Zhang WC, Lv BJ, Xiao H, Wang Q, Tu X, Liao YH, Shi GP, Cheng X. IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med (Berl). 2014;92(10):1105–16.

    Article  CAS  Google Scholar 

  21. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase I reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A. 2001;98:2871–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019–30.

    Article  CAS  PubMed  Google Scholar 

  23. Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D. Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology. 2016;221(3):412–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Roselló-Lletí E, Rivera M, Bertomeu V, Cortés R, Jordán A, González-Molina A. Interleukin-4 and cardiac fibrosis in patients with heart failure. Rev Esp Cardiol. 2007;60(7):777–80.

    Article  PubMed  Google Scholar 

  25. Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, Rhaleb N, Carretero OA, Rhaleb NE. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension. 2015;66(3):582–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J. 2010;12(3):158–62.

    PubMed  Google Scholar 

  27. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg. 2003;76(1):117–23.

    Article  PubMed  Google Scholar 

  28. Adampoulos S, Parissis JT, Parraskevaidis I, Karatzas D, Livanis E, Georgiadis M, Karavolias G, Mitropoulos D, Degiannis D, Kremastinos DT. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2003;24(24):2186–96.

    Article  Google Scholar 

  29. Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther. 2012;30(1):e30–40.

    Article  CAS  PubMed  Google Scholar 

  30. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103:485–92.

    Article  CAS  PubMed  Google Scholar 

  31. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB, Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–91.

    Article  CAS  PubMed  Google Scholar 

  32. Van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, Van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6(2):219–26.

    Article  CAS  PubMed  Google Scholar 

  33. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Hermann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–23.

    Article  CAS  PubMed  Google Scholar 

  34. McEvoy JW, Chen Y, Halushka MK, Christenson E, Ballantyne CM, Blumenthal RS, Christenson RH, Selvin E. Galectin-3 and risk of heart failure and death in blacks and whites. J Am Heart Assoc. 2016;5(5).

  35. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57–70.

    Article  CAS  PubMed  Google Scholar 

  36. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, O’Conner CM. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6(6):1172–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. • Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131(11):1019–30. This review discusses the interaction between immune cells and inflammatory signaling, with implications toward therapeutic targets.

    Article  PubMed  PubMed Central  Google Scholar 

  38. • Mehta JL, Pothineni NVK. Inflammation in heart failure: the holy grail? Hypertension. 2016;68:27–9. This review discusses the different effects of inflammation in acute versus chronic setting, particularly emphasizing the role of regulatory T cells.

    Article  CAS  PubMed  Google Scholar 

  39. •• Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum.”. J Am Coll Cardiol. 2016;67(9):1091–103. This review discusses the role of immune cells and inflammatory signaling in cardiovascular diseases, emphasizing the role of leukocytes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Aharinejad S, Abraham D, Paulus P, Zins K, Hofmann M, Michlits W, Gyöngyösi M, Macfelda K, Lucas T, Trescher K, Grimm M, Stanley ER. Colony-stimulating factor-1 transfection of myoblasts improves the repair of the failing myocardium following autologous myoblast transplantation. Cardiovasc Res. 2008;79:395–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106:1646–55.

    Article  CAS  PubMed  Google Scholar 

  43. Kain D, Amit U, Yagil C, Landa N, Naftali-Shani- N, Molotski N, Aviv V, Feinberg MS, Goitein O, Kushnir T, Konen E, Epstein FH, Yagil Y, Leor J. Macrophages dictate the progression and manifestation of hypertensive heart disease. Int J Cardiol. 2016;203:381–95.

    Article  PubMed  Google Scholar 

  44. Leuschner F, Courties G, Dutta P, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36:1478–88.

    Article  PubMed  Google Scholar 

  45. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.

    Article  CAS  PubMed  Google Scholar 

  46. Mann DL, McMurray JJV, Packer M, et al. Targeted anti-cytokine therapy in patients with chronic heart failure: results of the Randomized Etancercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602.

    Article  CAS  PubMed  Google Scholar 

  47. Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112:3408–14.

    Article  CAS  PubMed  Google Scholar 

  48. Parrillo JE, Cunnion RE, Epstein SE, Parker ME, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS. A prospective randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–8.

    Article  CAS  PubMed  Google Scholar 

  49. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083–8.

    Article  CAS  PubMed  Google Scholar 

  50. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998;351:1091–3.

    Article  CAS  PubMed  Google Scholar 

  51. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, Skudicky D, Sareli P. Effects of pentoxifylline on left-ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;90:1118–22.

    Article  CAS  PubMed  Google Scholar 

  52. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, Zambakides C, Peters F, Essop R. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004;109:750–5.

    Article  CAS  PubMed  Google Scholar 

  53. Torre-Amione G, Anker SD, Bourge RC, et al. Advanced chronic heart failure clinical assessment of immune modulation therapy investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomized trial. Lancet. 2008;371:228–36.

    Article  CAS  PubMed  Google Scholar 

  54. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ucland T, Lien E, Frøland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–5.

    Article  CAS  PubMed  Google Scholar 

  55. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–9.

    Article  CAS  PubMed  Google Scholar 

  56. Moreira DM, Vieira JL, Gottschall CA. The effects of METhotrexate therapy on the physical capacity of patients with ISchemia heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail. 2009;15:828–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Arkansas Veterans Healthcare System and the Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 Markham, Slot 532, Little Rock, AR, 72205, USA

    Lily F. Shirazi, Joe Bissett, Francesco Romeo & Jawahar L. Mehta

  2. University of Rome Tor Vergata, Rome, Italy

    Francesco Romeo

Authors
  1. Lily F. Shirazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joe Bissett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Romeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jawahar L. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jawahar L. Mehta.

Ethics declarations

Conflict of Interest

Lily F. Shirazi, Joe Bissett, Francesco Romeo, and Jawahar L. Mehta declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Evidence Based Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirazi, L.F., Bissett, J., Romeo, F. et al. Role of Inflammation in Heart Failure. Curr Atheroscler Rep 19, 27 (2017). https://doi.org/10.1007/s11883-017-0660-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-017-0660-3

Keywords

Search

Navigation